Abstract
Prior randomized studies suggested an overall survival (OS) benefit to the addition of short-term androgen deprivation therapy (ADT) in men with intermediate risk prostate cancer undergoing definitive external beam radiotherapy (EBRT). However, these studies were conducted in the setting of non-dose escalated EBRT, and did not include brachytherapy patients. Dose escalation of EBRT has been shown to improve local control, questioning the incremental benefit of adding ADT in this population, and brachytherapy is the most biologically escalated form of radiotherapy. Existing data are conflicting as to the incremental benefit of ADT in intermediate risk patients undergoing brachytherapy-based treatment. Our objective was to determine whether adding ADT improves the OS of patients with intermediate risk prostate cancer undergoing brachytherapy-based treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
